Detection of Circulating Tumor Cells and EGFR Mutation in Pulmonary Vein and Arterial Blood of Lung Cancer Patients Using a Newly Developed Immunocytology-Based Platform

• Published in: Diagnostics (Basel) Vol. 14; no. 18; p. 2064
• Main Authors: Dejima, Hitoshi, Nakanishi, Hayao, Takeyama, Ryo, Nishida, Tomoki, Yamauchi, Yoshikane, Saito, Yuichi, Sakao, Yukinori
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.09.2024; MDPI
• Subjects: Antibodies; Biopsy; circulating tumor cells (CTCs); Cytokeratin; cytology-based CTC detection platform; digital PCR; EGFR mutation analysis; Genetic aspects; Genetic testing; Histology; Kinases; Lung cancer; Metastasis; Microscopy; Mutation; Patients; Surgery; Tumors; Veins & arteries; Japan; United States > US; lung cancer; digital PCR; EGFR mutation analysis; circulating tumor cells (CTCs); cytology-based CTC detection platform
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14182064

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are powerful molecular targeted therapeutic agents for lung cancer. We recently developed an original immunocytology and glass slide-based circulating tumor cell (CTC) detection platform for both CTC enumeration and EGFR mutation analysis with DNA extracted from CTCs. Using this platform, we conducted a pilot clinical study for CTC enumeration in peripheral blood (PB), pulmonary arterial blood (PA), and pulmonary venous blood (PV) from 33 patients with lung cancer (Stage I-III) who underwent surgery, followed by digital PCR-based EGFR mutation analysis of CTCs in PV from 12 patients. The results showed that CTC levels were significantly higher in PV and PA than in PB ( < 0.05, < 0.01. respectively), with a notably greater number of small and large CTC clusters ( < 0.01). Genetic analysis of EGFR mutations of CTCs from PV ( = 12) revealed six mutations, including three Exon19del and three L856R, in CTCs and eight EGFR mutations, including five Exon19del and three L856R, in lung tumor tissue. CTC mutation status matched that of tissue samples in nine patients, was unmatched in two patients, and controversial in one patient, indicating a sensitivity of 0.75 (6/8) and specificity of 1.0 (4/4) with some false-negative results for the mutation analysis of CTCs. This immunocytology-based CTC detection platform is a convenient method for detecting both CTC number and EGFR mutation status under microscopy, suggesting its potential as a liquid biopsy tool in the hospital for patients with lung cancer in some clinical settings.